![]() ![]() He has contributed to the global approval of several medicines in virology, oncology, and autoimmune disease, and has published extensively in peer-reviewed journals. Earlier in his career, he served in leadership roles at AbbVie and Gilead Sciences. Ramanathan was responsible for building various scientific functions in discovery and development supporting pipeline expansion, regulatory submissions, and business development activities. He joins Roivant from Horizon Therapeutics where he served as Senior Vice President of Research and Development Sciences and Site Head of the South San Francisco office. Ramanathan has over 20 years of drug development expertise across a wide range of diseases. ![]() will be joining the company as Chief Development Officer. Collaborations with Blueprint Medicines, Janssen, and Boehringer Ingelheim include aggregate contingent milestone payments of over $1 billion as well as product royaltiesīASEL, Switzerland and LONDON and NEW YORK and BOSTON, (GLOBE NEWSWIRE) - Roivant Sciences (Nasdaq: ROIV) today announced that Srini Ramanathan, Ph.D.In addition to internal pipeline programs, Roivant companies Proteovant Therapeutics and VantAI have formed external drug development partnerships with leading companies to further innovate in protein degradation.Srini Ramanathan has over 20 years of experience in drug development and joins Roivant from Horizon Therapeutics where he built scientific R&D capabilities and teams to advance the company’s preclinical and clinical portfolio Srini Ramanathan, Chief Development Officer at Roivant Sciences ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |